# GOREISAN for Heart Failure (GOREISAN-HF) Trial

Study · id `cardio:ct-nct04691700` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04691700](<https://clinicaltrials.gov/study/NCT04691700>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04691700

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1179 participants.

## Technical summary

Registry record NCT04691700. Randomized; no masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1179 participants (enrolled count; ClinicalTrials.gov record NCT04691700, source copy `cardio:ctgov-nct04691700-2026-01-06`, retrieved 2026-10-26)
- Started: 2021-01-19 (actual) (ClinicalTrials.gov record NCT04691700, source copy `cardio:ctgov-nct04691700-2026-01-06`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04691700, source copy `cardio:ctgov-nct04691700-2026-01-06`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04691700, source copy `cardio:ctgov-nct04691700-2026-01-06`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT04691700, source copy `cardio:ctgov-nct04691700-2026-01-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04691700-2026-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: GOREISAN for Heart Failure (GOREISAN-HF) Trial
- Acronym: GOREISAN-HF
- Condition: Heart Failure
- Condition: Edema
- Condition: Traditional Japanese Medicine
- Condition: Kampo Medicine
- Condition: Clinical Trial
- Intervention (Drug): Goreisan
- Intervention (Drug): Standard Treatment
- Lead sponsor: Takeshi Morimoto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Takeshi Morimoto (`cardio:org-takeshi-morimoto`)

## Provenance

Content hash: fb6a07a419a83265276e77d564898c2d952f01a38f26a0f3a5e5713c0f731d5c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
